+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Analysis of the Global Human Albumin Market and Product Pipeline

  • ID: 3387663
  • Report
  • Region: Global
  • 60 Pages
  • Frost & Sullivan
1 of 5
Emerging Economies and Use of Human Albumin as an Excipient Present New Growth Opportunities

FEATURED COMPANIES

  • Celgene
  • CSL Behring
  • Grifols
  • Novo Nordisk
  • Novozymes
  • MORE
The study covers provides an assessment of the marketed and pipeline products for the global human albumin market. Segmentation by application has been provided along with additional information such as clinical trial timelines and results, and historical and projected launch timelines. The marketed and pipeline products have been broadly segmented into those used in replacement therapy (fluid-volume replacement therapy), in drug formulation and delivery, as stabilisers for vaccines, and as excipients in imaging and in-vitro fertilisation products. The market shares of the key companies operating in this space have also been listed.

Methodology and Scope

- This research service focuses on the global human albumin market and offers a detailed overview of human albumin use in replacement therapy (fluid-volume replacement therapy), drug delivery, as a stabiliser for vaccines, and as excipient coatings in imaging and in-vitro fertilisation products.

- A product and pipeline assessment is provided for both marketed and investigational human albumin products. The study covers the application of human albumin for therapeutic and non-therapeutic purposes.

- Products that have failed or been terminated, suspended, or recalled have not been covered.

The information contained in this research service was derived from published sources, including the following:

- Disease organisation websites
- Company publications, including annual reports
- Securities and Exchange Commission (SEC) filings
- Press releases
- US government public sources
- Published articles in scientific journals
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Celgene
  • CSL Behring
  • Grifols
  • Novo Nordisk
  • Novozymes
  • MORE
1. Executive Summary
1.1 Executive Summary - Key Findings
1.2 Key Trends
1.3 Key Companies to Watch

2. Methodology and Scope

3. Market Background
3.1 Market Overview - Introduction
3.2 Market Overview - Blood Plasma Production
3.3 Blood Plasma Market Share
3.4 Demand Analysis of Blood Plasma Proteins
3.5 Human Albumin Production
3.6 Market Forecast - Human Albumin
3.7 Market Forecast - Human Albumin Discussion
3.8 Supply Chain and Distribution Network
3.9 Porter’s 5 Forces Analysis
3.10 Human Albumin Market Share Analysis
3.11 Market Segmentation

4. Competitive Landscape - Human Albumin: Marketed and Pipeline Products
4.1 Recommendations for Data Center Operators
4.2 Competitive Landscape - Marketed and Pipeline Products
4.3 Marketed Products - Replacement Therapy
4.4 Pipeline Products - Replacement Therapy
4.5 Marketed Products - Drug Formulation and Delivery
4.6 Pipeline Products - Drug Formulation and Delivery
4.7 Marketed Products - Vaccine
4.8 Pipeline Products - Vaccine
4.9 Marketed Products - Others

5. Pivotal Trials - Phase 3 and Phase 2
5.1 Total Human Albumin Market - Major Ongoing/Recently Completed Clinical Trials
5.2 Summary of Key Products to Watch
5.3 Timeline of Key Events - Launch of Products

6. Product Dashboard - Key Marketed and Phase 3 Products
6.1 Product Dashboard: Albuminar - CSL Behring
6.2 Product Dashboard: Albutein - Grifols
6.3 Product Dashboard: Abraxane - Celgene
6.4 Product Dashboard: Victoza - Novo Nordisk
6.5 Product Dashboard: Recombumin - Novozymes
6.6 Product Dashboard: rIX-FP - CSL Behring

7. Conclusion
7.1 Legal Disclaimer
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Celgene
  • CSL Behring
  • Grifols
  • Novo Nordisk
  • Novozymes
  • MORE
- The global human albumin demand is likely to grow at a moderate rate of XX% during 2013-2020 driven by the use of albumin as a drug formulation agent, sealant, medical coating, and as an imaging and vaccine stabiliser.

- Human albumin production is driven by the global increase in fractionation of blood and the rising demand for human albumin in Asia-Pacific (APAC) nations such as China and India.

- The human albumin market is highly consolidated and dominated by top participants, namely, CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. Manufacturers are likely to adopt premium pricing to meet the emerging demand for human albumin in the non-therapeutic segment.

- The human albumin market is characterised by advancements in the use of human albumin protein as vehicle for the delivery of drugs and extension of the shelf life of drugs/biologics.

- These innovations are revolutionising the standard treatment regimen by reducing the requirement for additional doses or injections, better tolerance, and improved efficacy of the drug action.

- Human albumin has been widely used in clinical settings as a plasma expander or as replacement therapy. However, for over a decade, the use of human albumin as a non-therapeutic substance/excipient, that is, as a drug carrier, stabilising agent in vaccine, and as a sealant in surgeriesand coatings in medical devices and diagnostic kits is being explored and developed for commercial settings.

- There are a limited number of trials for human albumin used for therapeutic purposes. As of now, the key therapeutic use of human albumin (Albutein) in Alzheimer’s disease is being evaluated by Grifols.

- Most of the human albumin clinical trials are being evaluated for the non-therapeutic/excipient segment with regard to use of human albumin as a drug formulation agent, stabiliser, or fusion protein for half-life extension.

- The key pivotal products involving the use of albumin as a drug formulation agent, stabiliser, or fusion protein for half-life extension include:

- ABI-009: This is the nanoparticle albumin-bound (nab) version of the mTOR inhibitor sirolimus or rapamycin developed by Celgene, which licensed it out to AADi LLC, a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of Abraxane and nab technology.

- rIX-FP: Being developed by CSL Behring, rIX-FP is a recombinant fusion protein linking coagulation factor IX with albumin. It is indicated for the treatment of hemophilia B, with dosing intervals of up to days. CSL Behring has submitted a Biological License Application (BLA) for the Food and Drug Administration’s (FDA’s) approval in December 2014.

-Products such as Albutein for Alzheimer’s disease and CSL Behring’s rIX-FP are expected to be launched during the forecast period.
Note: Product cover images may vary from those shown
5 of 5
- CSL Behring
- Celgene
- Grifols
- Novo Nordisk
- Novozymes
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3387663
Adroll
adroll